Found 11 hits for monomerid = 50194721 Target/Host
(Institution) | Ligand | Target/Host
Links | Ligand
Links | Trg + Lig
Links | Ki
nM | ΔG°
kcal/mole | IC50
nM | Kd
nM | EC50/IC50
nM | koff
s-1 | kon
M-1s-1 | pH | Temp
°C |
|---|
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
| CHEMBL
PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.30 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9714234 (2017)
BindingDB Entry DOI: 10.7270/Q2474CW0 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US9714234 (2017)
BindingDB Entry DOI: 10.7270/Q2474CW0 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 4.40 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A... |
US Patent US9714234 (2017)
BindingDB Entry DOI: 10.7270/Q2474CW0 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase JAK2
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| US Patent
| n/a | n/a | 2.00E+3 | n/a | n/a | n/a | n/a | 7.4 | 25 |
Bristol-Myers Squibb Company
US Patent
| Assay Description
Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic... |
US Patent US9714234 (2017)
BindingDB Entry DOI: 10.7270/Q2474CW0 |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 630 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ... |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 19 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of BTK in human Ramos-B cells assessed as suppression of BCR/anti-IgG-stimulated Ca2+ flux after 1 hr incubation in dark by FLIPR1 assay |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 990 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ... |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.80 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen... |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 190 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of BTK in human whole blood assessed as suppression of BCR/anti-IgM/IgG-stimulated CD69 surface expression after 18 hrs with agitation by ... |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 2.30 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen... |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Tyrosine-protein kinase BTK
(Homo sapiens (Human)) | BDBM50194721
(CHEMBL3908310 | US9714234, 4)Show SMILES Cc1c(cccc1-n1c(=O)n(C)c2c(F)cccc2c1=O)-c1ccc(C(N)=O)c2[nH]c3cc(ccc3c12)C(C)(C)O |(15.71,-28.16,;14.37,-28.91,;13.05,-28.13,;11.71,-28.87,;11.68,-30.41,;13.01,-31.2,;14.35,-30.44,;15.68,-31.22,;15.66,-32.76,;14.31,-33.51,;16.97,-33.55,;16.95,-35.09,;18.31,-32.8,;19.63,-33.58,;19.61,-35.12,;20.98,-32.83,;20.99,-31.29,;19.67,-30.51,;18.34,-31.26,;17.01,-30.47,;17.03,-28.93,;13.08,-26.59,;14.43,-25.84,;14.45,-24.29,;13.12,-23.51,;13.14,-21.97,;14.48,-21.21,;11.82,-21.18,;11.78,-24.26,;10.31,-23.75,;9.38,-24.99,;7.85,-25.13,;7.2,-26.52,;8.07,-27.79,;9.61,-27.66,;10.27,-26.26,;11.75,-25.8,;5.66,-26.64,;4.26,-25.99,;5.53,-25.1,;5.01,-28.04,)| Show InChI InChI=1S/C32H27FN4O4/c1-16-18(7-6-10-25(16)37-30(39)22-8-5-9-23(33)28(22)36(4)31(37)40)19-13-14-21(29(34)38)27-26(19)20-12-11-17(32(2,3)41)15-24(20)35-27/h5-15,35,41H,1-4H3,(H2,34,38) | PDB
MMDB
NCI pathway
Reactome pathway
KEGG
UniProtKB/SwissProt
B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet
| CHEMBL
PC cid
PC sid
UniChem
Similars
| Article
PubMed
| n/a | n/a | 4.60 | n/a | n/a | n/a | n/a | n/a | n/a |
Bristol-Myers Squibb Research and Development
Curated by ChEMBL
| Assay Description
Inhibition of full length recombinant human His-tagged BTK expressed in baculovirus using fluoresceinated peptide incubated for 60 mins by fluorescen... |
J Med Chem 59: 9173-9200 (2016)
Article DOI: 10.1021/acs.jmedchem.6b01088
BindingDB Entry DOI: 10.7270/Q23T9K5H |
More data for this
Ligand-Target Pair | |
Search and Browse
